Teva Pharmaceutical Industries Ltd (ADR) (TEVA) Launches Minastrin Generic In The United States

Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) has unveiled the authorized generic version of Minastrin, an oral contraceptive that is c.....»»

Category: topSource: insidermonkeyMar 20th, 2017

Drugmaker Teva hires new CEO to restore its health

Teva Pharmaceutical Industries Ltd names H Lundbeck A/S Chief Executive Kare Schultz as its new CEO and president, as it struggles with heavy debts and fierce competition for its generic drugs in the United States. Amy Pollock reports.....»»

Category: videoSource: reutersSep 11th, 2017

Teva (TEVA) Launches Glumetza Generic, Inks Deal with Otsuka

Teva Pharmaceutical Industries Ltd. (TEVA) announced the launch of a generic version of Valeant Pharmaceuticals International, Inc.'s (VRX) diabetes drug, Glumetza, in the U.S. Teva .....»»

Category: topSource: zacksMay 16th, 2017

Teva Launches Authorized Generic of Allergan"s Minastrin

Teva Pharmaceutical I.....»»

Category: topSource: zacksMar 17th, 2017

Teva shares surge 2.2% after Mylan says it will delay generic Copaxone launch to 2018

Teva Pharmaceutical Industries Ltd. shares surged 2.2% in premarket trade Wednesday after Mylan NV said it plans to defer its generic Copaxon.....»»

Category: topSource: marketwatchAug 9th, 2017

Indian pharma poised for US acquisitions

Mumbai, 7 AugustThe assets of Teva Pharmaceutical Industries have become acquisition targets following devastating results announced last week by the world's biggest maker of generic medicines.Teva's profits in the second quarter dr.....»»

Category: topSource: business-standardAug 7th, 2017

Teva"s stock keeps plunging on heavy volume after Morgan Stanley downgrade

Shares of Teva Pharmaceutical Industries Ltd. tumbled 8% in morning trade Monday on heavy volume, putting them on track to close at a 14-year low, as Morgan Stanley turned bearish on the generic drug maker i.....»»

Category: topSource: marketwatchAug 7th, 2017

Is a Surprise in the Cards for Teva (TEVA) in Q2 Earnings?

While the inclusion of sales from Actavis Generics acquisition may continue to pull up Teva Pharmaceutical Industries Ltd.'s (TEVA) sales, its generic segment may see weakness. .....»»

Category: worldSource: nytJul 31st, 2017

How approval of a low-price generic HIV prevention drug could hit Gilead

Foster City's Gilead Sciences won approval in 2012 of Truvada as the first drug to prevent the spread of the AIDS virus. What does it mean now that Teva Pharmaceutical Industries has won the OK to introduce a supposedly low-cost version of the drug?.....»»

Category: topSource: bizjournalsJun 9th, 2017

Teva"s Stock Inches Higher Amid Cost-Cutting Plan

Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA), the troubled Israel-based generic and specialty medicines developer, confirmed with Bloomberg a plan to lower expenses and better manage its debt. read more.....»»

Category: blogSource: benzingaMar 23rd, 2017

The world’s biggest generic drugs producer is cutting 6,000 jobs: report

Teva Pharmaceutical Industries Ltd. plans to cut as many as 6,000 jobs, or about 11 percent of its global workforce.....»»

Category: topSource: moneycentralMar 23rd, 2017

Teva Pharmaceutical Industries Ltd (ADR) (TEVA), Mylan N.V. (MYL) Accused Of Price Fixing By 20 More States

The number of states accusing Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) and Mylan N.V. (NASDAQ:MYL) for price collusion have rise.....»»

Category: topSource: insidermonkeyMar 2nd, 2017

Manufacturing Delay Of Generic Drug From Pfizer Inc. (PFE) A Relief For Teva Pharmaceutical Industries Ltd (ADR) (TEVA)

Pfizer Inc. (NYSE:PFE) has been slapped with a warning letter by the Food and Drug Administration in regards to one of its fill/finish fac.....»»

Category: topSource: insidermonkeyFeb 22nd, 2017

Teva Pharmaceutical Industries Ltd. Reports Q4 Improvement Thanks to Actavis Deal

The generic and specialty drugmaker posts higher revenue in Q4 because of growth from a key acquisition......»»

Category: topSource: foxnewsFeb 13th, 2017

Teva CEO exits in ongoing crisis of confidence at drugmaker

Teva Pharmaceutical Industries was left without a permanent chief executive on Tuesday after Erez Vigodman stepped down, leaving new management to restore confidence in the world's biggest generic drugmaker after a series of missteps......»»

Category: topSource: foxnewsFeb 7th, 2017

Teva CEO exits amid crisis of confidence at drugmaker

TEL AVIV (Reuters) - The chief executive of Teva Pharmaceutical Industries has stepped down, leaving new management to overhaul the world's biggest maker of generic drugs and restore confidence after a series of missteps sent its shares plummeting......»»

Category: topSource: reutersFeb 7th, 2017

Teva, CEO part ways

Erez Vigodman has stepped down as president and CEO of Teva Pharmaceutical Industries Ltd. and left the generic drug company's board of directors. Teva (NYSE: TEVA) described the departure as a mutual agreement between the board and Vigodman. The chan.....»»

Category: topSource: bizjournalsFeb 7th, 2017

The CEO of generic drugmaker Teva just stepped down (TEVA)

Thomson ReutersFeb 6 (Reuters) - Israel-based generic drugmaker Teva Pharmaceutical Industries Ltd said on Monday that Chief Executive Erez Vigodman was stepping down effective immediately and would be replaced on an interim basis by Yitzhak.....»»

Category: topSource: businessinsiderFeb 6th, 2017

Teva CEO Erez Vigodman Steps Down

He's been CEO of the company since 2014. Israel-based generic drugmaker Teva Pharmaceutical Industries said on Monday that Chief Executive Erez Vigodman was stepping down effective immediately and would be replaced on an int.....»»

Category: europeSource: fortuneFeb 6th, 2017

Why United Parcel Service, Inc. (UPS), Teva Pharmaceutical Industries Ltd (ADR) (TEVA) and Under Armour Inc (UAA) Are 3 of Today’s Worst Stocks

InvestorPlaceInvestorPlace - Stock Market News, Stock Advice & Trading Tips Under Armour (UAA), Teva Pharmaceutical Industries (TEV.....»»

Category: topSource: investorplaceJan 31st, 2017

Court invalidates 4 Teva patents for MS drug

The U.S. District Court in Delaware ruled four of Teva Pharmaceutical Industries Ltd.'s patents for Copaxone were invalid, dealing Teva its latest setback in the company's efforts to ward off generic competition for its top revenue-producing product. T.....»»

Category: topSource: bizjournalsJan 31st, 2017